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Parkinson’s disease (PD) is a neurodegenerative syndrome
associated with selective loss of dopaminergic neurons in
the striatum. It is believed that both mitochondrial
dysfunction and oxidative stress (OS) play important role
in the pathogenesis of PD. Development of an effective
causal therapy should be focused on preventing or at least
retarding the neurodegenerative process underlying the
disease.
In chronic in fusion PD model studied the effect of
rotenone on the content, and release of striatal neuro-
transmitters of rat upon OS by H2O 2 perfusion. The
effects of anti-Parkinsonian drugs were examined in vitro
rotenone PD, OS slices model. The role of P2X7 receptor
(P2X7r) formed by 1-methyl-4-phenyl-1,2,3,6- tetrahydro-
pyridine (MPTP) or in vitro rotenone treatment using
C57/BI6 and P2X7r knockout mice. Neurochemical
response was determined using microvolume perfusion
method, HPLC separation of dansylated samples.
Dopamine o-quinone (DAQ) oxidized metabolite of DA
was detected electrochemically at -100 mV potential in
reduction working mode.
The dopamine content in the rat striatum is decreased
in response to chronic intravenous rotenone infusion.
However, surviving dopaminergic neurons take up and
release only a slightly lower amount of DA in response to
electrical stimulation. Striatal dopaminergic neurons
showed increased susceptibility to OS, responding with
enhanced release of DA and with formation of toxic meta-
bolite DAQ. The loss of DA and ATP and formation of
DAQ induced by OS confirmed the impairment of stria-
tum upon in vitro rotenone. Formation of DAQ at the end
effect of OS confirmed the impairment of dopaminergic
function by rotenone. However, when applied rotenone
with l-DOPA treatment the endogenous DAQ was
detected in perfusion samples. However, when applied
rotenone with l-DOPA treatment the endogenous DAQ
was detected in the micro-volume perfusion samples. Con-
versely, when rasagiline and trolox were in use these
DA-quinones metabolites were not detectable. Rotenone
treatment elicited a similar reduction in ATP content in
the substantia nigra of both genotypes, whereas reduction
of ATP was more pronounced after rotenone treatment in
striatal slices of P2X7 deficient mice. Although the level of
the endocannabinoid, 2-AG, was elevated by rotenone in
the striatum of wild-type mice, an effect that was absent in
mice deficient in P2X7 receptors. Genetic deletion of
P2X7 receptors did not change depletion of striatal endo-
genous DA content after in vivo MPTP or in vitro rote-
none treatment. Although the endogenous amino acids
content and the level of the endocannabinoid, AEA was
elevated by MPTP in the striatum of mice, but 2-AG
remained unchanged in mice deficient in P2X7 receptors.
In conclusion, oxidative stress induced, pathological DA
release and the formation of toxic metabolites of DA are
distinctly modified by the tested antiparkinsonian drugs
and P2X7 receptor deficiency does not promote the survi-
val of dopaminergic neurons.
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